Evidence map›Paper›PMID 36710965›Full record

ArticleFrontiers in cellular and infection microbiology2022

Differentially culturable tubercle bacteria as a measure of tuberculosis treatment response.

Julian S Peters, Amanda McIvor, Andrea O Papadopoulos, Tshepiso Masangana, Bhavna G Gordhan, Ziyaad Waja, Kennedy Otwombe, Matebogo Letutu, Mireille Kamariza, Timothy R Sterling and 3 more

Abstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Beyond culturability: VBNC-like and differentially culturableFrontiers in cellular and infection microbiology · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. PersistentiScience · 2024
    Article
  9. Article
  10. Clinical Strains ofPathogens (Basel, Switzerland) · 2024
    Article
  11. Article
  12. The performance of tongue swabs for detection of pulmonary tuberculosis.Frontiers in cellular and infection microbiology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Julian S PetersDepartment of Science and Innovation/National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, The National Health Laboratory Service, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Amanda McIvorDepartment of Science and Innovation/National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, The National Health Laboratory Service, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Andrea O PapadopoulosDepartment of Science and Innovation/National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, The National Health Laboratory Service, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Tshepiso MasanganaDepartment of Science and Innovation/National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, The National Health Laboratory Service, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Bhavna G GordhanDepartment of Science and Innovation/National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, The National Health Laboratory Service, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Ziyaad WajaPerinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
Kennedy OtwombePerinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
Matebogo LetutuPerinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
Mireille KamarizaDepartment of Biology, Stanford University, Stanford, CA, United States.
Timothy R SterlingVanderbilt University Medical Center, Nashville, TN, United States.
Carolyn R BertozziDepartment of Chemistry, Stanford University, Stanford, CA, United States.
Neil A MartinsonDepartment of Science and Innovation/National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, The National Health Laboratory Service, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Bavesh D KanaDepartment of Science and Innovation/National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, The National Health Laboratory Service, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Funding

Chemical MycobateriologyR37AI051622 · NIAID · STANFORD UNIVERSITY · PI BERTOZZI, CAROLYN · 2016 to 2025
$4.7M
Howard Hughes Medical InstituteNIAID NIH HHS R37 AI051622
6 · The paper itself

Abstract

Introduction: Routine efficacy assessments of new tuberculosis (TB) treatments include quantitative solid culture or routine liquid culture, which likely miss quantification of drug tolerant bacteria. To improve these assessments, comparative analyses using additional measures such as quantification of differentially culturable tubercle bacteria (DCTB) are required. Essential for enabling this is a comparative measure of TB treatment responses using routine solid and liquid culture with liquid limiting dilutions (LLDs) that detect DCTB in sputum. Methods: We recruited treatment-naïve TB patients, with and without HIV-infection, and serially quantified their sputum for DCTB over the course of treatment. Results: Serial sputum sampling in 73 individuals during their first 14 days of treatment demonstrated that clearance of DCTB was slower compared to routine solid culture. Treatment response appeared to be characterized by four patterns: (1) Classic bi-phasic bacterial clearance; (2) early non-responders with slower clearance; (3) paradoxical worsening with an increase in bacterial count upon treatment initiation; and (4) non-responders with no change in bacterial load. During treatment, LLDs displayed greater bacterial yield when compared with quantitative solid culture. Upon treatment completion, 74% [46/62] of specimens displayed residual DCTB and within this group, two recurrences were diagnosed. Residual DCTB upon treatment completion was associated with a higher proportion of MGIT culture, GeneXpert, and smear positivity at two months post treatment. No recurrences occurred in the group without residual DCTB. Discussion: These data indicate that DCTB assays detect distinct subpopulations of organisms in sputum that are missed by routine solid and liquid culture, and offer important alternatives for efficacy assessments of new TB treatments. The residual DCTB observed upon treatment completion suggests that TB treatment does not always eliminate all bacterial populations, a finding that should be investigated in larger cohorts.

Indexed as

Mycobacterium tuberculosisTuberculosisBacterial LoadHumansSputumcolony forming unitsdifferentially culturable tubercle bacteria (DCTB)most probable number (MPN)resuscitationtuberculosis

Identifiers

PMID36710965
PMCPMC9877613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.